Search results
Results From The WOW.Com Content Network
Purpose. test cognitive impairment. The Addenbrooke's Cognitive Examination (ACE) and its subsequent versions (Addenbrooke's Cognitive Examination-Revised, ACE-R [ 1] and Addenbrooke's Cognitive Examination III, ACE-III) are neuropsychological tests used to identify cognitive impairment in conditions such as dementia .
The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) is a questionnaire that can be filled out by a relative or other supporter of an older person to determine whether that person has declined in cognitive functioning. The IQCODE is used as a screening test for dementia. If the person is found to have significant cognitive ...
[123] [128] Mary L. Trump recounted that as her grandfather's dementia progressed, he failed to recognize people he had known for decades, including her and Donald. [129] [128] The latter stated that he first noticed his father exhibit symptoms of Alzheimer's in the mid-1990s. [130] [128]
In some cases, phrasing activities as a question can cause confusion for a dementia patient, experts warned. "Using empathy and understanding instead of frustration is crucial in managing these ...
August 19, 2024 at 1:30 AM. Dementia has 2 shocking new risk factors, study finds, with total of 14 now on list. Two surprising new risk factors for Alzheimer’s disease are noted in a new study ...
Radiation-induced cognitive decline describes the possible correlation between radiation therapy and cognitive impairment. Radiation therapy is used mainly in the treatment of cancer. Radiation therapy can be used to cure, care or shrink tumors that are interfering with quality of life. Sometimes radiation therapy is used alone; other times it ...
ADAS-Cog. The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials [ 1] and is considered to be the “gold standard” for assessing antidementia treatments.
The onset of the deficits has been between the ages of 40 and 90 years and finally there must be an absence of other diseases capable of producing a dementia syndrome. Possible Alzheimer's disease : There is a dementia syndrome with an atypical onset, presentation or progression; and without a known etiology; but no co-morbid diseases capable ...